MATN (f/k/a OXGN) -51% on phase-2/3 failure in ovarian cancer and termination of CA4P development (after all these years): http://investor.mateon.com/releasedetail.cfm?ReleaseID=1041745 The drug MATN will now focus on, OXI4503, has been in development for 14 years! Check the date on this post: #msg-2166339.